{"database": "lobbying", "table": "lobbying_activities", "rows": [[3809059, "76bd107c-d9f3-4d65-a60c-8876ffe501a3", "Q1", "F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES", 18411, "F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES", 2026, "first_quarter", "MED", "(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough", "HOUSE OF REPRESENTATIVES,SENATE", null, 160000, 0, 0, "2026-04-15T11:32:42-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3809059"], "units": {}, "query_ms": 0.4183900309726596, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}